Skip to content
Biotechnology

Moolec Confirms US Harvest and Promising Yields for Plant-Grown Products GLASO(TM) and Piggy Sooy(TM) in October

Moolec Science SA 2 mins read

LUXEMBOURG / ACCESSWIRE / September 5, 2024 / Moolec Science SA (NASDAQ:MLEC) ("The Company", "Moolec"), a science-based food ingredient company, announced today the harvest confirmation of US campaigns for genetically engineered plant-grown products GLASO™ and Piggy Sooy™ during October 2024.

GLASO™ and Piggy Sooy™ US Harvest Announcement
GLASO™ and Piggy Sooy™ US Harvest Announcement

GLASO™ (gamma-linolenic acid -GLA- in safflower oil) campaign located in Idaho consists of 600 planted acres of genetically modified safflower, mainly for commercial purposes. As a result of the harvest, Moolec is expecting to produce between 300 to 400 tons of safflower seeds that contain high levels of GLA. To allocate most of the upcoming GLASO™ production, Moolec has secured an offtake agreement with a major global CPG company, targeting the US market in 2025. Following a successful and rigorous audit from Moolec's CPG customer, production is set to begin in late 2024.

The Company is also developing a broader commercial strategy to reach larger markets and clients. Moolec's GLASO™ product contains almost 3 times more GLA than conventional sources such as borage and primrose oil, making it the most concentrated GLA oil available on the market.

Piggy Sooy™ (porcine myoglobin in soybean seeds) field trials are being carried out in 3 different US locations: Ohio, Missouri and Iowa. Main purposes for the campaign are product development (sampling), seed increase and gathering of environmental and regulatory data to continue Moolec's US-FDA approval pathway. The Team also projects a remarkable first open field performance for its bioengineered soybean Piggy Sooy™ after recent approval for cultivation from USDA-APHIS. This has set an unprecedented milestone in biotechnology last April, with Moolec becoming the first Molecular Farming company to obtain this kind of clearance for food crops growing animal proteins in US territory.

Chief Technology Officer and Co-Founder Martín Salinas stated: "Our commitment to scaling Moolec's Molecular Farming Technology is demonstrated by our GLASO™ campaign and the field trials of Piggy Sooy™. These efforts not only reinforce our position as pioneers in the industry but also lay the foundation for sustainable solutions in agriculture and biotechnology." He then finished by remarking: "One acre of Piggy Sooy™ could potentially produce pork meat proteins equivalent to 10 pigs, reducing water footprint, land usage and CO2 emissions. This is a clear demonstration on how we promote environmental improvements throughout all our operations. Our aim is to heal the meat production system."

Contact Information

Press & Media
[email protected]

Investor Relations
[email protected]

Related Files

Moolec Confirms US Harvest And Promising Yields For Plant-Grown Products GLASO™ And Piggy Sooy™ In October - 2024.09.05

SOURCE: Moolec Science

.

View the original press release on newswire.com.

More from this category

  • Biotechnology, Medical Health Aged Care
  • 10/04/2026
  • 11:12
Aravax

Aravax Strengthens Board with Appointments of Carsten Hellmann and Andrew Oxtoby

Aravax, a clinical-stage biotechnology company developing next-generation, disease-modifyingimmunotherapies for food allergy, today announces two additions to its Board of Directors, former CEO of ALK-Abello A/S, Carsten Hellmann and former Chief Commercial Officer of Aimmune Therapeutics, Andrew Oxtoby. Collectively, Carsten and Andrew bring to Aravax exceptionally deep experience from the pharmaceutical industry and, specifically, the allergy therapeutics field. Andrew has deep pharmaceutical industry expertise spanning development, product launch, fundraising and exits from working with large and small companies in the U.S. and Europe. As Chief Commercial Officer he built the global commercial organisation for the approval and launch in the US…

  • Biotechnology, Business Company News
  • 10/04/2026
  • 08:00
Cartherics Pty Ltd

Cartherics and Catalent Expand Commercial License Agreement

Melbourne, Australia, and Tampa, FL –Cartherics Pty Ltd, a biotechnology company developing off‑the‑shelf immune cell therapies for high‑impact women’s diseases, including ovarian cancer and endometriosis, and Catalent, Inc., the leader in enabling the development and supply of better treatments for patients worldwide, today announced an enhanced partnership. The companies have signed an amended commercial license agreement enabling the use of a Catalent cGMP‑compliant induced pluripotent stem cells (iPSC) line for the manufacture and commercialization of Cartherics’ iPSC-derived Chimeric Antigen Receptor Natural Killer (CAR-NK) cell therapies. The agreement supports Cartherics’ mission to develop immune cell therapy productsfor the treatment of cancer…

  • Biotechnology, Environment
  • 09/04/2026
  • 13:00
Ecopha Biotech

Ecopha Biotech Signals Global Expansion with Australia-India Pongamia Bioeconomy Strategy

Key Facts: Ecopha Biotech announces strategic Australia-India partnership to commercialise their ecopha.bio technology™ for Pongamia-based bioeconomy Technology converts Pongamia oil into sustainable aviation fuel…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.